← Leaderboards
Raymond J Budde
Houston Pharmaceuticals, Inc.
$1,574,986
Attributed
$1,574,986
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $430.3K · FY2007–16$500K$375K$250K$125K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$1,574,986 · 5
By mechanism
R44$840,603 · 1
R43$734,383 · 4
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoTumorMalignant NeoplasmsSolid NeoplasmPharmaceutical PreparationsChemotherapyResponseCancer CellPre-ClinicalDrug Delivery SystemsProteinsSmall Business Innovation Research GrantProductionCytokineDoseClinical TrialsInhibitor/AntagonistOperative Surgical ProceduresPropertyGlioblastomaBrain NeoplasmsAntigen TargetingImmunosuppressive AgentsImmune Response
Grant awards (6)
HIGHLY INNOVATED TARGETED THERAPY OF MELANOMA$281,165
R43 · FY2016 · CA · contact PI
Preclinical development of WP1066, an effective inhibitor of STAT3 activation for$410,341
R44 · FY2011 · AI · contact PI
Preclinical development of WP1066, an effective inhibitor of STAT3 activation for$430,262
R44 · FY2010 · AI · contact PI
Inhibition of STAT-3 to stimulate immune function for GBM$146,989
R43 · FY2008 · AI · contact PI
Thermally Targeted Delivery of DOX$179,980
R43 · FY2007 · CA · contact PI
Development of the first topo II inhibitor for brain tumors$126,249
R43 · FY2007 · CA · contact PI